Short-term variability of Alzheimer’s disease plasma biomarkers in a mixed memory clinic cohort

Table 1 Baseline characteristics

	AD (N = 27)	non-AD (N =20)	p-*value*
Age, years	71.4 (5.4)	72.1 (6.2)	0.65 ⁽¹⁾
Gender, Male	15 (55.6%)	16 (80.0%)	0.08 ⁽²⁾
MMSE, Mean (SD)	26.8 (2.5)	27.0 (2.2)	0.79 ⁽¹⁾
ACE, Mean (SD)	78.8 (8.4)	78.0 (11.0)	0.77 ⁽¹⁾
Disease severity			0.42 ⁽²⁾
- MCI	13 (48.1%)	12 (60.0%)
- Mild dementia	14 (51.9%)	8 (40.0%)
CSF Aβ1–42, pg/mL, Mean (SD) (AD n = 21, non-AD n = 18)*	664.8 (245.3%)	1124.2 (465.4%)	0.0004⁽¹⁾
CSF T-tau, pg/mL, Mean (SD) (AD n = 21, non-AD n = 18)*	317.2 (128.8%)	235.4 (122.7%)	0.05⁽¹⁾
CSF p-tau181, pg/mL, Mean (SD) (AD n = 21, non-AD n = 18)*	32.8 (15.2%)	20.7 (12.3%)	0.01⁽¹⁾
BMI, Mean (SD)	24.8 (3.4)	26.8 (5.3)	0.14 ⁽¹⁾
HbA1c, mmol/mol, Mean (SD)	40.6 (6.4)	40.8 (7.4)	0.95⁽¹⁾
eGFR,mL/min/1.73m2, Mean (SD)	82.9 (13.7)	80.1 (26.1)	0.64 ⁽¹⁾
Creatinine, pmol/L, Mean (SD)	73.7 (17.7)	90.3 (42.4)	0.08 ⁽¹⁾
Diabetes II, Yes	3 (11.1%)	6 (30.0%)	0.10 ⁽²⁾

MCI mild cognitive impairment, non-AD: DLB n = 6, Dementia with Lewy bodies, FTD n = 2, Frontotemporal dementia, head trauma n = 1; VD n = 1, Vascular dementia, CAA n = 2, cerebral amyloid angiopathy, ALS + VD n = 1, amyotrophic lateral sclerosis, NPH n = 1, normal pressure hydrocephalus, other tauopathy n = 1, affective disorder n = 1; kidney failure n = 1; unclassified n = 3. P-values from CSF are based on log-10-scale-transformed data. BMI 25–29.9: n = 11, BMI > 30: n = 8. HbA1c > 48mmol/mol: n = 8. eGFR < 60mL/min/1.73m2: n = 5. Creatinine: Female < 46: n = 1, > 90: n = 9 & Male < 60: n = 10, > 105: n = 4
⁽¹⁾two-way sample t-tests
⁽²⁾Pearson’s Chi-squared test
*n = 8 patients’ CSF were analyzed by Innotest (AD n = 6 (Aβ1–42 867.0 (73.1) pg/mL, T-tau 506.7 (160.2) pg/mL, p-tau 72.0 (22.1) pg/mL) and non-AD n = 2 (Aβ1–42 1176.0 (168.3) pg/mL, T-tau 255.0 (72.1) pg/mL, p-tau 39.0 (4.2) pg/mL))

ISSN: 1758-9193